Tag: HIV

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).

ViiV Healthcare received positive opinion for Juluca in Europe

viiv healthcare
ViiV Healthcare, the global specialist HIV company, announced that the CHMP has issued a Positive Opinion recommending marketing authorisation for Juluca for the treatment of HIV infection.

ChemRar has started the production of HIV drug

Aids
ChemRar, a Russian company based in the business incubator of the city of Khimki, began to produce a drug for HIV‐infected patients. This is not a cure for AIDS, but a so-called “preventive drug”.

Share of Russian HIV and cancer drugs increased significantly

manufacturing
The share of Russian-made medicines in the List of Vital and Essential Drugs increased by 10% in monetary terms over the five past years. This was announced by the Deputy Minister of Industry and Trade of the Russian Federation.

GSK brings legal action against Gilead Sciences

gsk
ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Ltd., announced that it has filed patent infringement litigation against Gilead Sciences

Russia increases its budget for antiretroviral drugs by 20% in 2018

Aids
The Russian Ministry of Health wants to prevent disruptions in the supplies of antiretroviral drugs. This year, the budget of the Ministry allocated 21.6 billion rubles for this purpose.

GlaxoSmithKline launches its HIV drug in China

Aids
British pharmaceutical giant GlaxoSmithKline has officially launched its blockbuster triple-therapy HIV drug in China, pricing it lower than in neighboring markets

Gates Foundation invests $40 million in Immunocore’s efforts

gates foundation
Immunocore Limited today announced an investment from the Bill & Melinda Gates Foundation to support the development of soluble TCR-based therapeutics for infectious diseases

30 major drugs against HIV infection are registered in Russia

skvortsova
The cost of drugs for the treatment of patients with HIV infection has decreased by half in eighteen months, said the Russian Health Minister Veronika Skvortsova

Gilead Sciences allows Belarus to buy medicines at lower prices

belarus
According to Lyudmila Reutskaya, the Head of Department of Pharmaceutical Inspection and Drug Supply Organization, Belarus is included in the list of countries covered by voluntary licensing agreements of Gilead Sciences

Bavarian Nordic and Janssen will collaborate on HIV-1 and HBV vaccines

janssen j&j
Bavarian Nordic yesterday announced an additional worldwide exclusive license and collaboration agreement with Janssen Pharmaceuticals

An innovative Russian drug registered for treatment of HIV infection

viriom chemrar
ELPIDA®, a new generation non-nucleoside reverse transcriptase inhibitor and the first original Russian drug in the 21st century for the treatment of HIV infection, was registered in Russia

Johnson & Johnson reported about promising clinical data for HIV vaccine

johnsonandjohnson
Johnson & Johnson today announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies

ABL gained $318 million contract for HIV vaccine development

hiv-vaccine
ABL Inc., a global contract research and manufacturing service provider, yesterday has been awarded the recompetition of the contract for “Preclinical Development Support”

RBV Capital will invest 44 million rubles for treatment of HIV infection

gene
Advanced Gene & Cell Technologies (AGCT), a resident of Skolkovo, received the first tranche of financing from RBV Capital

Generic of current AIDS drug will be used in Kenya

kenya
Kenya is the first country in Africa to introduce a generic version of the current drug of choice for people living with HIV

GSK put submissions for HIV treatment to EMA and FDA

gsk
GlaxoSmithKline (GSK) and ViiV Healthcare, the global specialist HIV company majority-owned by GSK yesterday announced regulatory submissions to the European Medicines Agency (EMA) and US Food and Drug Administration (FDA)